BioXcel Therapeutics (NASDAQ:BTAI) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.
This is a breakdown of current recommendations and price targets for BioXcel Therapeutics and Ultragenyx Pharmaceutical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
46.5% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 95.6% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 9.4% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
BioXcel Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.
This table compares BioXcel Therapeutics and Ultragenyx Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares BioXcel Therapeutics and Ultragenyx Pharmaceutical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioXcel Therapeutics||N/A||N/A||-$82.17 million||($3.79)||-8.37|
|Ultragenyx Pharmaceutical||$271.03 million||20.29||-$186.57 million||($5.28)||-15.36|
BioXcel Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioXcel Therapeutics beats Ultragenyx Pharmaceutical on 7 of the 13 factors compared between the two stocks.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.